Literature DB >> 1967979

Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein.

D Marquardt1, S McCrone, M S Center.   

Abstract

HL60 cells isolated for resistance to Adriamycin are multidrug resistant and defective in the cellular accumulation of drug. These cells do not however overexpress mdr1 and do not contain detectable levels of P-glycoprotein. In the present study we have prepared antisera against synthetic peptides that correspond to various sequence domains of P-glycoprotein and have examined by Western blot analysis the reactivity of these antisera with proteins contained in membranes of HL60/Adr cells. All antisera are highly reactive with a Mr 180,000 (p180) P-glycoprotein contained in membranes of HL60 cells isolated for resistance to vincristine (HL60/Vinc). In contrast, of 13 antisera tested 12 do not react with any resistance-associated protein in the HL60/Adr isolate. One antiserum (ASP14) is however highly reactive with a Mr 190,000 protein (p190) contained in HL60/Adr membranes. This protein is not detected in drug-sensitive cells. ASP14 also reacts with proteins p195 and p50 contained in a second independent HL60/Adr isolate. Analysis of membrane subfractions shows that p190 is located primarily in the endoplasmic reticulum with only low levels contained in plasma membranes. Additional studies demonstrate that endoplasmic reticulum of HL60/Adr cells contain a major Mr 190,000 protein that is capable of binding the photoaffinity agent 8-azido[alpha-32P]ATP. p195 contained in a second HL60/Adr isolate is also labeled with 8-azido[alpha-32P]ATP. These results thus demonstrate that antiserum against a specific P-glycoprotein sequence detects a p190 (p195) resistance-associated membrane protein in two independent HL60/Adr isolates. p190 (p195) and P-glycoprotein thus contain a minor sequence homology and based on the specificity of ASP14 this occurs in a region which may be involved in nucleotide binding. Possibly this sequence is common to and essential for the functionality of proteins which contribute to resistance by reducing cellular drug levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967979

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  Active efflux mechanisms for antimicrobial resistance.

Authors:  S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 2.  MRP subfamily transporters and resistance to anticancer agents.

Authors:  G D Kruh; H Zeng; P A Rea; G Liu; Z S Chen; K Lee; M G Belinsky
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

3.  The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.

Authors:  Taryn E Dick; Jeremy A Hengst; Todd E Fox; Ashley L Colledge; Vijay P Kale; Shen-Shu Sung; Arun Sharma; Shantu Amin; Thomas P Loughran; Mark Kester; Hong-Gang Wang; Jong K Yun
Journal:  J Pharmacol Exp Ther       Date:  2015-01-06       Impact factor: 4.030

Review 4.  Management of listeriosis.

Authors:  H Hof; T Nichterlein; M Kretschmar
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

5.  ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump.

Authors:  I Leier; G Jedlitschky; U Buchholz; M Center; S P Cole; R G Deeley; D Keppler
Journal:  Biochem J       Date:  1996-03-01       Impact factor: 3.857

Review 6.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 7.  Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug.

Authors:  M S Center
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

8.  Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells.

Authors:  P F Lenehan; P L Gutiérrez; J L Wagner; N Milak; G R Fisher; D D Ross
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 9.  Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.

Authors:  B T Hill
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.

Authors:  Ivana Gojo; Ming Tan; Hong-Bin Fang; Mariola Sadowska; Rena Lapidus; Maria R Baer; France Carrier; Jan H Beumer; Bean N Anyang; Rakesh K Srivastava; Igor Espinoza-Delgado; Douglas D Ross
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.